Abdel-Baki, A., Ouellet-Plamondon, C. & Malla, A. (2012). Pharmacotherapy challenges in patients with first-episode psychosis. Journal of Affective Disorders, 138 (Suppl.), S3–S14.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists & North American Association for the Study of Obesity. (2004). Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596–601.
American Psychiatric Association. (2006). American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Arlington, VA: Author.
Benowitz, N.L. (2009). Pharmacology of nicotine: addiction, smoking-induced disease and therapeutics. Annual Review of Pharmacology and Toxicology, 49, 57–71.
Bishara, D. & Taylor, D. (2008). Upcoming agents for the treatment of schizophrenia: Mechanism of action, efficacy, tolerability. Drugs, 68, 2269–2292.
Brands, B. (Ed.). (2000). Management of Alcohol, Tobacco and Other Drug Problems: A Physician's Manual. Toronto:Centre for Addiction and Mental Health.
Canadian Pharmacists Association. (2011). Compendium of Pharmaceuticals and Specialties 2011. Toronto: Author.
Canadian Psychiatric Association. (2006). Clinical practice guidelines: Management of anxiety disorders. Canadian Journal of Psychiatry, 51 (Suppl. 2). Retrieved from http://publications.
Canadian Psychiatric Association. (2005). Clinical practice guidelines: Treatment of schizophrenia. Canadian Journal of Psychiatry, 50 (Suppl. 1). Retrieved from ww1.cpa-apc.org
Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P.T., Churchill, R. et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. The Lancet, 373, 746–758.
College of Physicians and Surgeons of Ontario. (2010). Methadone maintenance treatment for opioid dependence. Dialogue, 2, 1–8. Retrieved from www.cpso.on.ca
Collins, P.Y., Patel, V., Joestl, S.S., March, D., Insel, T.R., Daar, A.S. et al. (2011). Grand challenges in global mental health. Nature, 475, 27–30.
Duval, F., Lebowitz, B.D. & Macher, J-.P. (2006). Treatments in depression. Dialogues in Clinical Neuroscience, 8, 191–206.
Edens, E., Massa, A. & Petrakis, I. (2010). Novel pharmacological approaches to drug abuse treatment. Current Topics in Behavioral Neurosciences, 3, 343–386.
Fuller, M.A. & Sajatovic, M. (2006). Drug Information Handbook for Psychiatry: Including Psychotropic, Nonpsychotropic, and Herbal Agents. Hudson, OH: Lexi-Comp.
Hajek, P., Stead, L.F., West, R., Jarvis, M. & Lancaster, T. (2009). Relapse prevention interventions for smoking cessation (Review). Cochrane Database of Systematic Reviews, 2009(1), CD003999.
Hasin, D.S., Stinson, F.S., Ogburn, E. & Grant, B.F. (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States. Archives of General Psychiatry, 64, 830–842. Retrieved from http://archpsyc.jamanetwork.com
Kane, J.M., Barrett, E.J., Casey, D.E., Correll, C.U., Gelenberg, A.J., Klein, S. et al. (2004). Metabolic effects of treatment with atypical antipsychotics. Journal of Clinical Psychiatry, 65, 1447–1455.
Kreek, M.J., LaForge, K.S. & Butelman, E. (2002). Pharmacotherapy of addictions. Nature Reviews: Drug Discovery, 1, 710–726.
Lam, R.W., Kennedy, S.H., Grigoriadis, S., McIntyre, R.S., Milev, R., Ramasubbu, R. et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders, 117 (Suppl. 1), S26–S43. Retrieved from www.canmat.org
Little, A. (2009). Treatment-resistant depression. American Family Physician, 80, 167–172. Retrieved from www.aafp.org
McDonough, M.S., Peterson, K., Carson, S. et al. (2008). Drug class review: Atypical antipsychotic drugs—Final report update. Portland, OR: Oregon Health & Science University. Retrieved from www.ncbi.nim.nih.gov
Merck Canada. (2012). Saphris: Product Monograph. Kirkland, QC: Author.
Merikangas, K.R., Jin, R., He, J-.P., Kessler, R.C., Lee, S., Sampson, N.A. et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry, 68, 241–251. Retrieved from http://archpsyc.jamanetwork.com
Olfson, M., Marcus, S.C., Tedeschi, M. & Wan, G.J. (2006). Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry, 163(1), 101–108.
Retrieved from http://ajp.psychiatryonline.org
Ravindran, L.N. & Stein, M.B. (2010). The pharmacologic treatment of anxiety disorders: A review of progress. Journal of Clinical Psychiatry, 71, 839–854.
Sullivan, J.T., Sykora, K., Schneiderman, J., Naranjo, C.A. & Sellers, E.M. (1989). Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction, 84, 1353–1357.
Sun-Edelstein, C., Tepper, S.J. & Shapiro, R.E. (2008). Drug-induced serotonin syndrome: A review. Expert Opinion on Drug Safety, 7, 587–596.
Tonstad, S., Tønnesen, P., Hajek, P., Williams, K.E., Billing, C.B. & Reeves, K.R. (2006). Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA, 296(1), 64–71. Retrieved from http://jama.jamanetwork.com
Trivedi, M.H., Lin, E.H.B. & Katon, W.J. (2007). Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectrums, 12 (Suppl. 13), 1–27.
Veilleux, J.C., Colvin, P.J., Anderson, J., York, C. & Heinz, A.J. (2010). A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clinical Psychology Review, 30, 155–166.
Virani, A.S., Bezchlibnyk-Butler, K.Z., Jeffries, J.J. & Procyshyn, R.M. (Eds.). (2011). Clinical Handbook of Psychotropic Drugs (18th rev. ed.). Toronto: Hogrefe & Huber.
Yatham, L.N., Kennedy, S.H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R. et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disorders, 7 (Suppl. 3), 5–69.
Yatham, L.N., Kennedy, S.H., Schaffer, A., Parikh, S.V., Beaulieu, S., O'Donovan, C. et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disorders, 11, 225–255. Retrieved from http://onlinelibrary.wiley.com